HIFU Side Effects
Ablatherm HIFU has fewer significant side effects than other forms of prostate cancer treatment.
Ablatherm HIFU is a very safe procedure with no reported mortality and minimal morbidity. Over 30,000 patients have been treated worldwide since the Ablatherm HIFU device received European approval in 2000. HIFU also offers early success determination with nadir PSA after only 3 months.
Better quality of life is maintained with the HIFU procedure and repeat treatments are possible.
Will I Need Further Tests?
A quarterly measurement of the PSA is recommended for the first two years, and biannual tests are recommended in years three and four.
Thereafter we recommend an annual PSA test. Three to six months after the treatment the PSA should be reduced to 0.5 ug/l.
If the PSA reading does not return to very low levels or rises, a repeat ultrasound and biopsy can be performed. If this biopsy shows residual tumor (approximately 7% of Canadian cases), a second Ablatherm® HIFU session can be conducted. A major advantage of Ablatherm ® HIFU is that it is repeatable and does not preclude future treatment by any other treatment options. A bone scan and CAT scan would also be ordered. If biopsies are negative but the PSA rises, additional therapy may be prescribed.
Summary of Ablatherm® HIFU Complications Reported Throughout the World
The chart below describes the complications of using the Ablatherm® HIFU device for treatment as primary care of localized prostate cancer based on experience from around the world:
|Mild to moderate urinary incontinence||8%|
|Total urinary incontinence||<1%|
|Sexual impotence with nerve-sparing procedure||10%|
There have been no digestive system complications reported when Ablatherm® HIFU was used in the initial treatment of T-1 or T-2 cancer of the prostate.
In the cases where Ablatherm® HIFU was used in patients with previous radiation treatment failures, there were some reports of a feeling of mild rectal burning.